NECTAGEN INC

Biotech · Private

Bioprocess-compatible affinity chromatography resins using nanoCLAMP antibody mimetic ligands for plasma protein purification

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Total capital: $1.7M

Federal grants: $1.4M; 7 awards · 2018–2024; Rank in peer group#2 of 54
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: $300K; 2 awards · Health and Human S; Rank in Biotech#269 of 4373
Granted patents: 1; 5 pending · first 2021; Rank in peer group#17 of 54

Capital timeline

Latest events

Jul 2024Federal grantHealth and Human S · Phase I · Development of Custom nanoCLAMP Affinity Chromatography Resins for Fast, Efficient Purification of Plasma Proteins$275K
May 2023Federal grantHealth and Human S · Phase I · Development of an Orally Available Therapeutic for Neutralizing C. difficile Toxin B$275K
Jul 2021Federal grantHealth and Human S · Phase I · Development of DNA-Labeled Antibody Mimetics as Low-Cost, High-Performance Reagents for Single Cell Analysis of Membrane Proteins$252K
Jul 2019Federal grantHealth and Human S · Phase I · Development of Enzyme Replacement Therapy for Complement C2-Deficiency$150K
Sep 2018Federal grantHealth and Human S · Phase I · Affinity reagents for the sub-fractionation of specific exosomal populations$150K
Aug 2018Federal grantHealth and Human S · Phase I · Affinity reagents for the sub-fractionation of specific exosomal populations$150K
Mar 2018Federal grantHealth and Human S · Phase I · Generation of High Resolution Antibody Mimetics to Improve the Visualization of Subcellular Structures by Super Resolution Microscopy$150K

Show 2 earlier federal awards

Sep 2011Federal contractHealth and Human S · SBIR Topic 294 Phase I - Development Of Glycosylation - Specific Research$150K
Sep 2010Federal contractHealth and Human S · TAS::75 0849::TAS Development Of Alternative Affinity Capture Reagents For Cancer Proteomics Research.$150K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 54 peers

Line = median

Biotech · Material

Federal grants#2 · top 4%
Granted patents#17 · top 31%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 1 granted of 6

Jul 9, 2026PendingThermostable Binding ScaffoldsUSPTOApplication 19133337
Feb 16, 2021GrantedAffinity Proteins And Uses ThereofUSPTOUS 10,919,981
PendingThermostable Binding ScaffoldsUSPTOApplication PCTUS2023081399

Show all 6 patent records

Thermostable Binding ScaffoldsJul 9, 2026 · Application 19133337Pending
Affinity Proteins And Uses ThereofFeb 16, 2021 · US 10,919,981Granted
Thermostable Binding ScaffoldsApplication PCTUS2023081399Pending
Thermostable Binding ScaffoldsApplication 63428344Pending
Affinity Proteins And Uses ThereofApplication PCTUS2015046588Pending
Affinity Proteins And Uses ThereofApplication 62040772Pending

Coordination Pharmaceuticals IncSimilar federal contract value in Biotech · $300K in contracts
Regulus Therapeutics Inc.Similar federal contract value in Biotech · $300K in contracts
ADT PHARMACEUTICALS, LLCSimilar federal contract value in Biotech · $300K in contracts
HYLAPHARM LLCSimilar federal contract value in Biotech · $300K in contracts
Ribonova Inc.Similar federal contract value in Biotech · $299K in contracts
TREVIGEN, INC.Similar federal contract value in Biotech · $299K in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.